ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2011
Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Pooled it
- The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013Pooled it
- Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2015Trial
- Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial.The international journal of cardiovascular imaging · 2013Trial
- Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients.Current opinion in pharmacology · 2023Review
- The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Asystole following Regadenoson administration: Review of literature, risk factors and management.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Review
- Role of Cardiac AFrontiers in pharmacology · 2020Review
- Evidence for Arrhythmogenic Effects of AFrontiers in pharmacology · 2019Article
- Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Review
- ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Article
- Safety and tolerability of regadenoson CMR.European heart journal. Cardiovascular Imaging · 2014Article
- Use of regadenoson in end-stage renal disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013Article
- Prevalence and significance of electrocardiographic changes and side effect profile of regadenoson compared with adenosine during myocardial perfusion imaging.Journal of cardiovascular disease research · 2013Article
- Patient-centered imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012Article
- Nuclear cardiology: 2014 innovations and developments.Methodist DeBakey cardiovascular journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacokinetic studies suggest delayed clearance of Regadenoson (REG), a new selective A2A receptor agonist in chronic kidney disease (CKD). The safety of REG in large series of CKD patients in daily clinical practice remains unstudied.
methodsRetrospective study of patients with eGFR < 60 mL/min (n = 411, Grp 1, CKD) were compared to patients with eGFR ≥ 60 mL/min (n = 638, Grp 2, Control) undergoing REG-SPECT from Jan to Nov 2009. Patient demographics, REG-SPECT data, side effects, and arrhythmia occurrences were evaluated.
resultsNo major adverse events were noted immediately after REG-SPECT or at 1 week of follow-up. There were no differences in any arrhythmias in between the two groups (Grp 1, 47.2% vs Grp 2, 42.9%, P = ns). Ninety-nine percent of arrhythmias in CKD patients were PACs or PVCs. Transient junctional rhythm was observed in one CKD patient. There were no occurrences of second degree or higher degree AV block. Grp 1 had a blunted heart rate response (16.6 ± 16.1 vs 24.9 ± 20.3 bpm, P ≤ .001) and greater systolic blood pressure drop response (-7.4 ± 21.1 vs -1.4 ± 20.9 mm Hg, P ≤ .001) compared to Grp 2. Transient headache was more in Grp 2 (15.8% vs 22.6%, P ≤ .007). Aminophylline use to ward-off the side effects was comparable (9.5% vs 9.9%, P = ns).
conclusionREG-SPECT can be safely performed in CKD non-dialysis patients with excellent tolerability, minimal side effects, and favorable hemodynamic responses compared to control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.